Cancer Drug CADD522 Rebuilds Mouse Bone and Melts Away Menopause Fat

Eight weeks after surgeons removed the ovaries of sixteen female mice, a scanner pressed thin X-ray beams through their shin bones, hunting for the honeycomb of trabecular struts that oestrogen loss usually dissolves. In these mice, a molecule called CADD522, built years earlier to choke off a protein called RUNX2 (a switch that guides an embryo’s skeleton but appears to turn against bone once oestrogen falls), rebuilt that honeycomb almost as if the surgery had never happened. The same drug stripped fat from the animals’ hips and bone marrow, without any change in how much they ate. A compound aimed originally at cancer was quietly doing two menopause-era jobs at once.

Osteoporosis alone is a large problem to solve twice over with one molecule. It affects around one in three women and one in five men over 50 worldwide, and a hip fracture carries roughly a 20 percent chance of death within a year.

A Bone Switch Working Backwards

RUNX2 is best known for the opposite job to the one it appears to play here. During development, it is the master switch that tells stem cells to become bone-building osteoblasts, and without it embryos are born with no mineralised skeleton at all. Researchers at the University of East Anglia, or UEA (a UK research university that led the study), had already been testing a RUNX2 blocker, CADD522, against cancers that hijack the same protein to spread. Blocking a bone-building switch to help bone sounds backwards, but developmental roles and adult, diseased-tissue roles can diverge sharply, and that gap is exactly where this result sits. In ovariectomised mice, three doses of CADD522 a week for eight weeks raised a blood marker of new bone formation without budging a separate marker of bone breakdown, a pattern that reads as added construction rather than reduced demolition.

That distinction matters because most existing osteoporosis drugs work the other way round. Bisphosphonates and similar drugs mostly slow the demolition crew; they do not add builders.

Under the microscope, the difference showed up as more than a number on a scan. Mice that had lost their ovaries and received only a vehicle solution showed sparse, isolated clusters of the bone-dissolving cells that break down old tissue, alongside a marrow choked with fat. Mice on CADD522 showed those same cells back in wider, more continuous rows along the bone surface, doing their normal turnover job rather than sitting idle in a fat-clogged marrow.

“But the biggest surprise came when we looked beyond bone health,” says Dr Darrell Green of UEA’s Norwich Medical School, who led the work. “The mice receiving CADD522 weighed less than their untreated counterparts despite eating the same amount of food.” That pattern, fat loss with no drop in appetite, is the same signature an old shelved compound called TOFA (5-tetradecyloxy-2-furoic acid) showed in obese miceearlier this year, though the two drugs work through entirely different targets. The animals also carried less fat around their hips and fewer fat deposits inside their marrow, a build-up that is common after menopause and is itself linked to weaker bone.

The Same Switch, a Second Job in Fat

The metabolic story went deeper than a bathroom scale. When the team analysed fatty acids in the animals’ brains, three per group, they found that CADD522 shifted the balance of fat types back toward the pattern seen in mice that still had functioning ovaries. Several saturated fats that build up after ovary loss fell; a couple of monounsaturated fats that had dropped came back up. Levels of DHA (docosahexaenoic acid), an omega-3 fat linked to brain health, stayed essentially flat either way, so the drug was not simply flooding the system with every kind of fat. “We didn’t directly test for memory or thinking ability,” Green says, “but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”

None of that helps a patient if the drug cannot survive being swallowed. Here the safety data offered a cautious green light. Given by mouth to mice, rats and dogs, CADD522 reached the bloodstream in each species, with dogs absorbing 67.5 percent of an oral dose. A lab test that measures how tightly the drug grips its target, run across a range of concentrations, found it locking on at just 116 nanomolar, and a follow-up experiment confirmed that only a specific chemical group on the molecule made this possible; close chemical cousins missing that group did nothing.

The drug does not linger, though. In mice its half-life ran to roughly an hour; in dogs, closer to forty minutes. Liver tissue from mice, rats, dogs, minipigs and people, tested side by side in the lab, broke the drug down fastest in the rodent samples and slowest in the human ones, hinting that a dose which barely lasts in a mouse might sit around longer in a person. Eight days of high, twice-daily oral dosing in mice produced only mild side effects, a modest dip in white blood cells and a small rise in liver enzymes and cholesterol, not the kind of red flag that usually ends a drug’s story early.

What the mouse data cannot yet answer is whether stronger bones and a leaner build actually add up to fewer broken hips, and the study itself says as much: this is a single ovariectomy model, run for eight weeks, with brain chemistry sampled from only three animals per group. The molecular chain connecting a cancer-linked protein switch to marrow fat and brain lipids also remains undrawn; CADD522 is engaging RUNX2, and RUNX2 is clearly not just a skeleton gene, but the intermediate steps are still a gap on the map. Full study and methodology: https://doi.org/10.1038/s44386-026-00076-z.

What is harder to dismiss is the shape of the result rather than its size. A single compound moved two systems, bone and fat, that menopause usually pulls apart in the same direction, in the same animals, on the same schedule, the kind of cross-tissue coordination that exercise-linked signalling molecules manage on a smaller scale. Drug hunters spend careers chasing side effects; this one arrived doing the opposite of what its designers were watching for, in a place they were not looking.

FAQ